The Autism studies/research thread

Post Reply New Topic

For decades, autism has been described as a spectrum - an elastic term that stretches from nonverbal children to adults with doctorates. Beneath that vast range lies a shared pattern of social communication and behavioral differences, long resistant to neat explanations.

Now, advances in brain imaging, genetics and computational science are revealing discreet biological subtypes. The discoveries could one day lead to more accurate diagnoses and treatments - raising profound questions about whether autism should be seen as something to cure or as an essential facet of human diversity.

There are a few high-impact mutations that alone appear to lead to autism. But researchers now suspect that the majority of cases arise from a subtler genetic architecture - common variants scattered throughout the population that, in certain combinations and under certain environmental conditions, can alter development.

And while recent public discourse has been clouded by misinformation about the role vaccines play in autism, Tylenol and what factors cause the condition, the new analysis is gradually illuminating the science of autism’s beginnings. It suggests that some children may have genetic mutations when they’re born that activate at different times in life - a reflection of varying paths that emerge at different moments.

Natalie Sauerwald is one of the lead authors of the subtypes study and a computational biologist at the Flatiron Institute, part of the Simons Foundation, which funds scientific research. She compared earlier autism research to assembling a jigsaw puzzle, only to find that the pieces didn’t quite fit - not because the image was unclear but because “the box had always contained several puzzles, shuffled together.”

There isn’t just one autism, Sauerwald said: “There are many autisms.”

When Sauerwald began analyzing the autism database managed by the Simons Foundation, a science nonprofit, and housing information on over 5,000 children, she expected the results to be messy. The spectrum spans such a wide range that she assumed the categories would blur together, like overlapping circles in a Venn diagram. Instead, the data resolved into four groups with their own genetic and behavioral signatures.

“That level of distinctiveness was really surprising,” she said.

The work published in July in Nature Genetics detailed the four categories.

-Broadly affected: The smallest group - about 10 percent of participants - faced the steepest challenges, marked by developmental delays, difficulties with communication and social interaction, and repetitive behaviors that touched nearly every part of life.
Advertisement

-Mixed autism with developmental delay: Roughly 19 percent showed early developmental delays but few signs of anxiety, depression or disruptive behavior. Researchers call this group “mixed” because its members vary widely in how strongly they display social or repetitive behaviors.

-Moderate challenges: About a third of participants fell into this group, showing the hallmark traits of autism - social and communication differences and repetitive habits - but in subtler ways and without developmental delays.

-Social and/or behavioral: The largest group, around 37 percent, met early developmental milestones on time yet often grappled with other conditions later on, including ADHD, anxiety, depression or obsessive-compulsive disorder.

In totality, hundreds of genetic mutations have been identified as being linked to autism.

Roughly half appear to be inherited - but the rest arise spontaneously, and it is these that are perhaps the most mysterious. These mutations come from random copying errors in DNA or from outside influences. The list of suspects impacting autism is long: air pollution, paternal age, maternal diabetes, prenatal infections - all supported by some evidence, though none yet definitive.
Advertisement

Sauerwald and Troyanskaya’s work illuminates the genetic blueprint of autism. But genes don’t act in isolation. Across laboratories, scientists are probing external forces, particularly the prenatal environment, to find out what might nudge those genes to switch on or off.

That curiosity has, at times, collided with politics. In recent months, scientists have been baffled by the Trump administration’s decision to single out Tylenol use in pregnancy as a possible cause. “There are other exposures with similarly not very strong statistical associations,” said Catherine Lord, a professor of psychiatry at UCLA and one of the field’s foremost experts, referring to work on SSRI antidepressants, fever, heavy metals and other possible prenatal and environmental associations. “Across these studies, the effect sizes are small.”

Zeyan Liew, an environmental epidemiologist at Yale, has spent years studying PFAS, also knows as “forever chemicals,” the synthetic compounds used in products like Teflon that now pervade food and drinking water. His National Institutes of Health-funded research, drawing on data from millions of children across three European countries, found no direct link between maternal PFAS levels and autism diagnoses. But the data hinted at something subtler: Children whose mothers had higher exposure tended to show more social and behavioral difficulties - hyperactivity, anxiety, trouble forming friendships.

“It shows that a mother’s PFAS level is correlated with a child’s social developmental functioning,” Liew said. The chemicals, he suspects, may act on the developing brain, disrupt hormonal balance or trigger oxidative stress - “unwanted biological interference,” he said, “during a period of rapid brain development.”

2025 has been a monumentally challenging year for scientists in general and for autism researchers in particular, but despite drastic federal funding cuts, scientists continued to make progress toward understanding autism’s causes, improving diagnosis, and developing more effective treatments and supports for individuals with autism and their families. According to an Autism Science Foundation survey, about $80 million in autism funding was eliminated early this year as part of Department of Government Affairs (DOGE) cuts. This included approximately $80 million in autism research across the NSF, CDC, and NIH. In September, we received some encouraging news when the NIH announced $50 million in funding for 13 projects under the new Autism Data Science Initiative (ADSI), which will utilize U.S. datasets to investigate gene–environment interactions. These studies will examine a range of environmental factors, individually and in combination, and explore their roles in autism prevalence and causation.

Meanwhile, there was substantial progress toward understanding the biology of autism, including new insights into causes and effective supports, and important findings on biological subtyping.

Heterogeneity: Studies Confirm Autism Subtypes
One of the clearest scientific themes of 2025 was progress in understanding the differences of people with autism across the spectrum. Large-scale biological and behavioral analyses published this year identified reproducible subgroups within autism, including groups that differ in genetic backgrounds, biological features, changes in behavioral features over time, and co-occurring medical or behavioral profiles. These studies have the potential to shift the field away from treating autism as a single, uniform condition toward stratified, precision approaches and targeted supports.

Researchers used artificial intelligence paradigms to identify behavioral patterns and group individuals by shared features. They then compared biological characteristics across these groups to identify underlying mechanisms. This work began last year, and the findings reported in 2025 have been among the most impactful to date in defining autism subtypes. Using this approach, one study identified four subtypes, including one that closely aligns with profound autism (“broadly affected”), another characterized by higher rates of psychiatric conditions such as anxiety or ADHD (“moderately affected”), and two groups with milder challenges.mAnother study found that age at diagnosis—early childhood versus adolescence—was the strongest predictor of subtype. Children diagnosed earlier tended to have delays in language, motor skills, and overall development, while those diagnosed later were more likely to have OCD, ADHD, or anxiety.nThose who are diagnosed later had co-morbid psychiatric issues that may have masked an autism diagnosis.

Genes are early determinants of biology and behavior, making it critical to understand how genetics contributes to these behavioral differences. These studies found that individuals with greater challenges tend to carry larger, rarer genetic variants, whereas those with milder or later-diagnosed autism show a higher burden of smaller, more common variants. Certain rare variants, known as de novo variants and not inherited from either parent, are associated with more severe autism features.

Looking beyond genetics to brain structure, additional studies showed that the severity of autism traits measured by the ADOS, both in individuals with autism and in individuals with ADHD, was a primary driver of differences in brain structure, rather than diagnostic category alone. The overlap in behavioral features, brain structure, and genetics across autism and many psychiatric disorders highlights the transdiagnostic nature of many neurodevelopmental traits calling into question existing diagnostic boundaries. Many of the brain changes studied, including differences in cell density, were similar in individuals with ADHD and autism and more dependent on severity of symptoms. Other studies demonstrated that autism-related brain differences are also present in individuals without an autism diagnosis who nonetheless show elevated autism traits. Taken together, these studies confirm that autism is not a single condition. As research progresses, a key priority will be to better understand subgroups within the broader non-profound autism population so that supports and services can be more effectively tailored.

Genetics and Environmental Factors
Individual functioning is influenced not only by genetics but also by environmental factors unique to each individual or family. These include chemical, nutritional, and contextual influences that warrant further study. While some environmental factors, like prenatal birth, may affect the probability of an autism diagnosis independent of genetic risk, they may also modify outcomes and capabilities in individuals who are already diagnosed. Scientists increasingly agree that a broad range of environmental exposures should be studied in relation to developmental outcomes across diagnostic boundaries and along a continuum, rather than focusing narrowly on autism alone.

This year, studies also helped exonerate environmental factors that are not related to autism, including acetaminophen. In 2025, global health authorities and scientific reviews reaffirmed that there is no proven causal link between Tylenol (acetaminophen) use during pregnancy and autism. Organizations such as the World Health Organization and the American Academy of Pediatrics noted that existing studies show inconsistent associations and do not establish causation. These clarifications came amid political claims suggesting a connection, prompting experts and advocacy groups like ASF to emphasize that autism’s causes are complex and not attributable to anything parents did or did not do before, during, or after pregnancy.

Sex Differences
Research in 2025 also advanced understanding of sex differences in autism, particularly the biological mechanisms that shape them. Large genomic datasets, built over decades, revealed why females are less frequently diagnosed than males. Females—especially those with cognitive and motor challenges—carry a higher burden of de novo variants than males, despite no difference in the specific genes affected. This pattern supports the concept of differential liability, in which females may have greater biological resilience to autism-related risk.

Additional findings suggest that sex differences arise from multiple mechanisms beyond a single female protective effect. Studies showed that female siblings of individuals with autism have language difficulties that are milder than those seen in autism but greater than those in unrelated peers. Other work found that although females are typically diagnosed later overall17, among children diagnosed before age two, females outnumber males. Females also have higher rates of co-occurring mental health conditions, which may complicate or delay diagnosis.18 These differences may reflect both biological variation and diagnostic bias, which could be addressed through clinician training and refinement of diagnostic instruments.19 For example, Black autistic girls are less likely to receive a diagnosis despite similar social responsiveness scores, underscoring the role of bias in diagnostic practices.

Other biological mechanisms underlying sex differences involve the X chromosome. Because females have two X chromosomes, understanding X-linked gene expression in both sexes is critical. Research in 2025 identified 33 X-linked variants consistently associated with autism.nThese variants are involved in brain development at different stages and show sex-specific expression patterns.Differences between X- and Y-linked genes may further contribute to sex differences in autism presentation and diagnosis.

Moving Toward Precision Medicine
In 2025, multiple studies used organoids and genetic medicines to advance targeted, personalized approaches for autism, particularly in individuals with known genetic conditions. Organoid and assembloid technologies allow scientists to observe early brain development and identify where developmental pathways diverge in autism. Organoids derived from an individual’s own cells can model that person’s unique neurobiology, enabling researchers to test how brain circuits develop and respond to interventions in a highly personalized way. For individuals with autism, this approach may help identify treatments tailored to specific genetic and cellular profiles rather than relying on one-size-fits-all strategies.

Organoids are being used to develop personalized interventions for conditions including FMR1-related disorders, Timothy syndrome, MECP2-related disorders, and Dup15q syndrome.
These studies include efforts to predict responses to anti-seizure medications and to better understand early cellular processes that influence autism risk.

Similarly, researchers made progress in genetic medicines, with early studies demonstrating the feasibility for autism linked to highly penetrant genetic variants. Approaches using antisense oligonucleotides (ASOs), CRISPR-based tools, and RNA repair strategies have advanced from animal models toward human trials, including clinical studies in Angelman syndrome and Rett syndrome. These advances are moving the field from gene discovery toward functional recovery. Additional progress has brought other potential therapeutics closer to autism-specific trials. While gene therapies target specific mutations, treatments developed for one rare genetic condition are now being explored in related conditions and, potentially, in idiopathic autism. Examples include trials of IGF-129,30 and metformin. Developing an evidence base for cross-disorder treatments will open the door to further expanding their utility in autism without an established genetic cause.

Predicting the Future Using a Longitudinal Design
Families often wonder how their child with autism will develop throughout their life and how they should prepare. Studying individuals over time, rather than at a single age, has revealed important insights into outcomes, including which features are likely to remain stable and which may improve. In general, individuals with lower baseline abilities tend to show more challenging developmental trajectories, although this pattern is not universal. Environmental factors, such as socioeconomic status, may also influence both baseline abilities and developmental trajectories. Cognitive ability was the most predictive of core autism symptom trajectory, indicating it strongly predicts ASD outcomes.

At a neurobiological level, developmental trajectories may be partially explained by autism-related differences in temporal lobe white matter development. Autistic brains show altered patterns of synaptic pruning during development, which may affect how neural circuits mature over time.

Research using rare and critical postmortem brain tissue from individuals with autism has begun to show how the autistic brain changes across the lifespan at a cellular level. However, this line of research is severely limited by the scarcity of available brain tissue. Future studies should examine distinct autism subtypes or subgroups—defined by behavioral features or co-occurring conditions—to better understand differences in brain development. Funding agencies should recognize the long-term value of longitudinal and tissue-based research and support sustained staffing, participant engagement, and the evolving needs of families followed over time.

Early Intervention Promotes Improvement
This year, scientists compiled large datasets to study predictors of early intervention outcomes. These studies examined a range of intervention modalities targeting core autism features. Researchers found that intervention effectiveness is influenced by factors such as duration and intensity, baseline skill levels at the start of intervention,mand earlier age at entry,but not by the specific name or branded model of the intervention. In other words, interventions with different names that focus on skill learning and the promotion of social and cognitive development were broadly beneficial.

By contrast, duration, intensity, and earlier age at entry were consistently associated with improvements in cognitive and language abilities.Because young children receive much of their social interaction from parents or other caregivers, parent involvement has proven to be a critical component of effective early intervention. These approaches are now being applied successfully to infants who show early signs of developmental challenges, extending intervention efforts to even earlier stages of development.

Managing Severe, Intense, and Dangerous Behaviors
Meaningful progress was also made this year in understanding severe, intense, and dangerous behaviors in autism. This included improved understanding of wandering, a behavior associated with increased risk of injury and death, and more common among autistic children than their non-autistic peers (DiGiuseppi), as well as the development of more effective interventions to reduce wandering (Scheithauer).

This year also saw increased research attention to catatonia, a potentially fatal condition that is more prevalent among individuals with autism and intellectual and developmental disabilities, yet often more difficult to recognize in autistic individuals than in those without an autism diagnosis (Smith). Cases of documented catatonia occur in about 10% of people with autism, although this might be an underestimation due to communication difficulties in individuals with autism, or changes in development over time that may be mistaken for a core autism feature. You will be hearing more about this issue from ASF in the future.

Conclusion
Despite political hostility and the spread of misinformation that disrupted some lines of research, autism scientists rose to the occasion in 2025. They shared discoveries that help families better understand the biological diversity of autism and the nature of different autism subtypes. These findings illustrate both the neurobiology underlying distinct forms of autism and the role environmental factors play in shaping outcomes. Research in 2025 also highlighted both the overlap and the unique features of autism compared with other neurodevelopmental conditions, such as ADHD. Together, these advances move the field closer to ensuring that the right person receives the right treatment at the right time.

There is a window of time, a critical period, during infancy and early childhood when the brain learns how to process information — what different objects look like, parsing sounds that make up language and how to navigate social interactions.

If the brain is not exposed to information during this critical period, some abilities never develop. For example, this is why some people who learn English as an adult cannot hear or pronounce the difference between “R” and “L” sounds.

New research from the Arizona State University Department of Psychology has shown that the cerebellum, a structure at the back of the brain that until recently was thought to contribute only to coordination and movement, is more involved in the brain’s critical period than previously understood.

A disruption in the interactions between the cerebellum and the rest of the brain during the critical period led to reduced social behaviors, especially in males, according to the work, which used animal models.

The cerebellar disruption also resulted in structural and functional changes in the cortex, the outermost areas of the brain, and subcortical regions located deep within the brain.

“During the critical period, the type of input the cerebellum is getting and the output it is sending affects more brain regions than previously thought. Our findings show that the cerebellum influences cortical and subcortical circuits that are involved in reward processing and social behaviors,” said Tristan Lyle, a psychology graduate student at ASU and first author on the study.

The study has been published in Molecular Psychiatry.

A possible role in autism
The researchers used a technique that merges chemistry and genetics to inactivate the lateral cerebellar nuclei, a group of neurons deep within each of the cerebellum’s two lobes.

These cerebellar cells were shut down during a time that corresponds to infancy in humans and that encompassed the critical period.

The effects were far reaching throughout the rest of the brain.

The lack of activity from lateral cerebellar nuclei affected neuronal activity in the ventral tegmental area, a brainstem region where dopamine neurons are located, the nucleus accumbens and the anterior cingulate cortex. A molecular marker showed decreased activity in this circuit, which is known to be involved in reward processing.

Inactivating the lateral cerebellar nuclei during the critical period also caused pronounced behavior changes — abolishing social behaviors in males.

These findings have implications for the understanding of autism, the researchers said, because the cerebellum is the most commonly affected brain region in the disorder.

If a baby experiences an injury to their cerebellum, as can happen during birth from stroke or lack of oxygen, their odds of being diagnosed with autism spectrum disorder increase by a multiple of 40.

“Autism is more likely to be diagnosed in the male population, which could be a result of diagnostic criteria that are skewed toward males. However, our findings show that the phenotype for social behavior in the paradigm we used was skewed toward males being affected by the cerebellum perturbation,” said Jessica Verpeut, assistant professor of psychology at ASU and senior author on the paper.

Glowing cells show cerebellum affects cortical neuron structure
The researchers used proteins that fluoresce, or glow, neon yellow to examine whether inactivating the lateral cerebellar nuclei affected the structure of neurons in the cortex.

In the anterior cingulate cortex, the dendrites were denser and more complex than if the lateral cerebellar nuclei had not been turned off. Dendrites are neuronal appendages that can look like tree branches and are the gateway for incoming information to neurons.

“These brain regions are not acting by themselves; they are all connected and are impacting each other across the lifespan,” Verpeut said. “We think that the cerebellum acts like a metronome, a timer, that contributes to the balance between excitatory and inhibitory functions in the brain.

"We really need to understand what other brain areas are involved because it could lead to relief of symptoms of neurodevelopmental disorders involving the cerebellum."

New research from the University of Missouri has identified a tool that could be useful in diagnosing kids in rural areas of the state where specialty care is less accessible.

The study tested an existing AI medical device, called CanvasDx, to see if it was helpful in identifying and diagnosing autism in children more efficiently and expeditiously.

University of Missouri pediatrics professor Dr. Kristin Sohl said the tool utilizes videos and questionnaires uploaded by parents, as well as feedback from rural physicians to predict a positive or negative autism diagnosis.

She said the hope is that tools such as this will reduce barriers to treatment — including time, costs and traveling distance — that rural families often face.

“The idea is to build capacity, so that if you live in a smaller community you still have access to the best practices that you need or the best practices that you want to access,” Sohl said.

According to the study, the average distance that families had to travel for specialist care was 97 miles, and by keeping the care in the local communities, families were able to receive an autism spectrum disorder diagnosis 5-7 months earlier.

Sohl said they found the tool to be helpful and it never contradicted a clinician’s assessment, but it was not yet effective enough to reliably replace a clinician.

“We definitely found that the device works well,” Sohl said. “And so, one of the things that we know is that autism is diagnosed by clinical experience, and so, when you're adding an AI device, you really want to make sure that the clinician and the device are aligned.”

She said there were many times that the device could not determine a positive or negative autism spectrum diagnosis, so it returned an “indeterminate result.” According to the study, the device reliably produced determinate results for just more than half (52%) of patients.

“That doesn't replace a human to support a child and their family after the diagnosis. What I hope is that this does accelerate the actual bottleneck around diagnosis, so that we can, kind of, move on, right?” Sohl said. “Like, fine, kiddo is on the spectrum. Now what?”

Sohl said there is still more work to be done before AI tools will be taking over from providers, but these tools can help rural primary care physicians be more confident in their decision-making.

She added there are other resources for rural primary care physicians who are looking to learn more about diagnosing autism spectrum disorders, such as the ECHO Autism.

This group virtually brings together a team of 20-40 clinicians, including rural providers and autism specialists, twice a month to consult on cases and share new autism developments.

It’s well-established that wildfire smoke, something that is becoming more frequent because of climate change, is bad for our health, causing asthma attacks, cough, congestion and worse.

Now, a new study gives even more reason to be concerned. Recent research published in the journal Environmental Science and Technology found that pregnant people who were exposed to wildfire smoke in their third trimester had a higher risk of having a child with autism.

The study was conducted by Tulane University researchers in New Orleans, who looked at recorded wildfire smoke in Southern California and examined data from 200,000 births between 2006 and 2014. The study’s authors estimated wildfire smoke exposure for each person by using the pregnant person’s address (or addresses, if they moved during the time) to determine smoke exposure levels and the number of smoke events. Researchers then looked at autism diagnoses from the baby’s providers.

Specifically, researchers looked at exposure to PM 2.5, which are particles commonly found in wildfire smoke that are 2.5 micrometers and smaller and can be inhaled and end up in the bloodstream. Colleen Reid, an environmental epidemiologist and health geographer with the University of Colorado Boulder, previously told HuffPost that no amount of PM 2.5 exposure is safe.

Tulane researchers found that the more time a pregnant person was exposed to wildfire smoke, the higher the risk of an autism diagnosis by age 5 for their child. It wasn’t about the wildfire smoke concentration, but rather the total number of days a pregnant person was exposed to smoke, lead study author David Luglio, a post-doctoral fellow with the Celia Scott Weatherhead School of Public Health and Tropical Medicine at Tulane University, told HuffPost.

When compared to a pregnant person with no wildfire smoke exposure, those who had more than 10 days of wildfire smoke exposure in their third trimester had a 23% higher chance of having a child with autism. When exposed to wildfire smoke for six to 10 days, that number dropped to 12%. Pregnant people exposed to one to five wildfire smoke days were 11% more likely to have a child with an autism diagnosis.

This study does have limitations. It is unknown if study participants evacuated during wildfire smoke events or if they used (or did not use) protective measures such as masks and indoor air filters.

“This is not definitive causation. It’s just an association. It’s a start to look at specific types of air pollution, and we can go from there,” Luglio told HuffPost.

The cause of autism is complicated and not totally known; it can be genetic, and research is ongoing to determine what environmental factors (such as air pollution) can also play a role.

“For me, the relationship between environmental policy and public health is one aspect to think about with this ... we’re getting better able to identify not just the genetic causes,” said Dr. Sinan Omer Turnacioglu, interim division chief of neurodevelopmental pediatrics and neurogenetics at Children’s National Hospital in Washington, D.C.

Turnacioglu, who was not affiliated with the study, told HuffPost that experts are starting to gain a “better awareness” of what could contribute to autism from an environmental standpoint. “This is a really important study along those lines,” he continued.

Dr. Hanna Stevens, a professor of psychiatry at the University of Iowa, told HuffPost that the new study has “some overlaps here with other things that have been studied with respect to air pollution. There have been a couple of big studies, actually by some of these same authors in the same data set ... of a relationship of particulate matter and exposure to air pollution with the diagnosis of autism.” Stevens was also not affiliated with the new study.

Existing research shows there may be a link between prenatal air pollution exposure and autism risk. “So, the fact that this dives deeper into that is actually helping us understand that relationship better and understand where to look further with more research ... that needs to be done,” Stevens noted.

Unlike past research, though, this study looks at wildfire smoke as an environmental pollutant and a stress exposure, Stevens added, “which combines different elements that I think matter for consideration of prenatal exposures.” Both stress and pollutants can be “disruptive” to a pregnant person’s health and, likely, a baby’s developing brain, Stevens said.

“We think that all of these things ― chemical exposure, stress experiences ― change the physiology of the mother, and probably change the physiology of the placenta, which is a combined maternal-fetal organ that is really responsible for everything that happens to the fetus,” Stevens explained. The placenta “provides a lot of supportive factors, transports nutrients from the mother, provides oxygen to the developing fetus.”

If the placenta is coping with a chemical exposure, this can increase oxidative stress within the cells in the placenta, Stevens said. This can impact the transportation of nutrients and also “have more direct effects on perpetuating oxidative stress in the developing fetus,” Stevens explained. “And all of these things are very, very important — nutrients, the level of oxidative stress, how cells are able to do what they’re supposed to do — for brain development.”

Moreover, study leaders found that the smoke exposure during the third trimester carried the highest risk of autism diagnosis.

“So, we’re really thinking about later stages of fetal-brain development ... I think there’s probably something about those later periods of brain development that’s increasing that risk,” Turnacioglu said.

billion people suffer from migraine headaches, the third most disabling neurological condition worldwide. The burden may be even greater among individuals with autism.

One study reports a lifetime migraine prevalence of approximately 42% among people with autism compared with roughly 20% in a control population.

Even these numbers likely underestimate the true rate due to lack of recognition and underreporting of migraine in general. In a recent UCLA study, migraine rates were elevated in cohorts of individuals with autism, despite conservative estimates in the datasets reviewed from the National Survey of Children's Health and the University of California Los Angeles hospital system electronic health.

The cohort study suggests that migraines are not merely incidental in this population. Rather, they are both more common and more severe, warranting greater diagnostic vigilance.

“The data trended toward higher severity and more frequent, chronic migraine,” says Sinifunanya Nwaobi, MD, PhD, pediatric neurologist and headache medicine specialist, assistant professor of neurology at UCLA, and lead author of the recently published UCLA study.

Dr. Nwaobi adds that the odds of severe headache were markedly increased by 4-fold. While migraine characteristics such as duration, nausea, light and sound sensitivity, and premonitory symptoms have not yet been exhaustively studied in relation to autism, these now form the next frontier of continuing investigation for the UCLA team.

“Do people with autism experience more or less of certain features? What is the ‘migraine experience in those with autism’ – from symptomatology to barriers to diagnosis? Hopefully, we will soon be able to provide more answers,” Dr. Nwaobi says.

Diagnostic blind spot
Clinical underrecognition is a central concern. During a typical office visit, migraine symptoms may be eclipsed by competing priorities. Behavioral concerns, epilepsy and gastrointestinal issues often take precedence when headache pain remains unvoiced or expressed differently by patients with autism.

“Communication barriers, particularly among nonverbal or minimally verbal patients who cannot describe sensory phenomena such as light sensitivity or nausea, further complicate the detection process,” explains Dr. Nwaobi.

This diagnostic blind spot is especially troubling given the functional impact caused by migraines. In pediatric populations, migraines are associated with increased school absenteeism, poorer academic performance, higher rates of grade retention and missed extracurricular activities.

“They rate their overall quality of life as poor, the same as children with cancer or chronic rheumatologic disease,” Dr. Nwaobi adds. “When layered onto autism, migraine’s cumulative burden is likely substantial, even if not yet fully quantified.”

The cause of migraines being more prevalent in autism remains something of a question mark, Dr. Nwaobi says. However, she believes one conceptual bridge lies in how the brain interprets and responds to sensory input.

“Migraine is a sensory processing disorder at its core, characterized not only by head pain but by sensory disruptions around light, sound, smell, balance, etc.,” she explains. “Autism, likewise, is defined in part by atypical sensory responses, ranging from sensory sensitivity to profound aversion to certain stimuli. There is overlap in abnormal sensory processing occurring in both autism and migraine, raising the possibility of a shared neurobiological vulnerability.”

Additionally, research shows that people with autism experience higher rates of central sensitization disorders. Conditions such as fibromyalgia, irritable bowel syndrome and chronic pain syndromes, all characterized by heightened central nervous system responsiveness, are overrepresented in patients with migraines and patients with autism. Whether this reflects shared mechanisms or parallel susceptibility remains unknown.

Diagnosis and treatment
For clinicians, the implications of the migraine/autism connection are practical and immediate. Dr. Nwaobi urges providers to maintain a lower threshold for considering migraines when autistic patients show changes in behavior, sleep, mood or concentration.

“Migraines should be part of physicians’ differential diagnosis,” she stresses, particularly when patients present with agitation or functional decline without an obvious cause. Family history of migraine is also an important diagnostic clue, as are behavioral cues such as retreating to dark rooms, aversion to lighted screens or increased distress in noisy environments.

Treatment principles remain largely the same for people with and without autism. Triptans, CGRP-inhibitors and other standard preventive strategies appear to be effective in autistic patients, though formal comparative trials are lacking.

“Clinicians should, however, be mindful that people with autism can be very sensitive to medications. Consider starting with a lower dose, titrating slowly, with frequent monitoring,” Dr. Nwaobi advises.

Additionally, she says alternative delivery systems and nonpharmacologic options, including neuromodulation devices, may be valuable for patients with sensory aversions or needle phobia.

Ultimately, the greatest gap in the migraines/autism conundrum is perceptual. Migraine remains underrecognized, underdiagnosed and undertreated even in the general population. In autism, where barriers to care are already substantial, that gap widens further.

“The first step is recognizing it,” Dr. Nwaobi says. “For physicians across disciplines, keeping migraine on the diagnostic radar may meaningfully improve quality of life for a population whose pain too often goes unseen.”

Abstract
Two decades of genetic studies in autism spectrum disorder (ASD) have identified more than 100 genes harbouring rare risk mutations1,2,3,4,5,6,7,8,9,10,11,12,13. Despite this substantial heterogeneity, transcriptomic and epigenetic analyses have identified convergent patterns of dysregulation across the ASD postmortem brain14,15,16,17. To identify shared and distinct mechanisms of ASD-linked mutations, we assembled a large patient collection of human induced pluripotent stem (hiPS) cells, consisting of 70 hiPS cell lines after stringent quality control representing 8 ASD-associated mutations, idiopathic ASD, and 20 lines from non-affected control individuals. Here we used these hiPS cell lines to generate human cortical organoids, profiling by RNA sequencing at four distinct time points up to 100 days after in vitro differentiation. Early time points harboured the largest mutation-specific changes, but different mutations converged on shared transcriptional changes as development progressed. We identified a shared RNA and protein interaction network, which was enriched in ASD risk genes and predicted to drive the observed downstream changes in gene expression. CRISPR–Cas9 screening of these candidate transcriptional regulators in induced human neural progenitors validated their downstream convergent molecular effects. These data illustrate how risk associated with genetically defined forms of ASD can propagate by means of transcriptional regulation to affect convergently dysregulated pathways, providing new insight into the convergent impact of ASD genetic risk on human neurodevelopment.

Abstract
Background: Autism spectrum disorder (ASD) prevalence has increased 80-fold from 2–4:10,000 in 1960 to 1:31 in children born in 2014, temporally correlating with expansion of the childhood vaccine schedule from 3 doses to 28 doses by age 2 years (Pearson r = 0.91, p = 0.0015). Despite this correlation, aluminum adjuvants have never undergone dedicated neurotoxicity testing, and the 1986 National Childhood Vaccine Injury Act shields manufacturers from liability. This manuscript evaluates whether aluminum adjuvants contribute to ASD in genetically susceptible individuals.

Methods: We reviewed over 200 peer-reviewed studies (1965–2025) spanning immunology, neuropathology, epidemiology, genetics, and toxicology, organized using the Bradford Hill criteria for causation. Analysis included mechanistic pathways, postmortem neuropathology, genetic susceptibility factors, epidemiological correlations, animal models, and autoimmune syndrome parallels.

Results: Evidence satisfies all nine Bradford Hill criteria for causation. Aluminum adjuvants activate the NLRP3 inflammasome, triggering IL-1β production, blood-brain barrier compromise, microglial activation, T-lymphocyte infiltration, astrocyte attack, and complement-mediated synaptic pruning dysregulation. Postmortem studies reveal perivascular T-lymphocyte cuffs in 65% of ASD brains versus 5% of controls (13-fold increase), with elevated CD8+/CD4+ ratios and granzyme B expression indicating cytotoxic immune attack. Additional findings include astrocyte damage, microglial activation, dysregulated complement components (C1q, C3, C4), elevated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IFN-γ), and glutamate transporter abnormalities consistent with excitotoxic vulnerability.

Genetic variants create vulnerability: HLA-DR4 alleles confer significantly increased ASD risk; MTHFR C677T and A1298C polymorphisms (present in 40–60% of ASD cases) impair glutathione synthesis; GST variants impair aluminum detoxification; and complement gene variants alter synaptic pruning thresholds. These factors render individuals unable to adequately detoxify aluminum or mount controlled immune responses during critical developmental windows (3 months–3 years).

When reviewed in detail, this proposed mechanism of aluminum adjuvants in the pathogenesis of ASD meets all nine of the Bradford Hill criteria for causation, which strongly supports a causal relationship.

Conclusions: Converging mechanistic, neuropathological, epidemiological, and genetic evidence demonstrates that aluminum adjuvants can trigger ASD in genetically susceptible individuals through well-characterized neuroinflammatory pathways. The 80-fold increase in ASD prevalence temporally correlating with vaccine schedule expansion, combined with robust biological mechanisms and postmortem findings, demands urgent re-examination of aluminum adjuvant safety in the context of neurodevelopment, particularly in genetically vulnerable populations.

CONCLUSION
The autism spectrum disorder (ASD) crisis confronting global public health in 2025—with
prevalence at 1 in 31 children [Shaw et al., 2025] and cumulative lifetime costs exceeding
$460 billion annually in the United States alone [Leigh & Du, 2015]—demands a response
grounded in scientific rigor, epidemiological honesty, and regulatory accountability. The
preceding six chapters establish a comprehensive mechanistic, neuropathological, genetic,
and legal framework linking aluminum adjuvant exposure to ASD in genetically susceptible
individuals through NLRP3 inflammasome activation, IL-1β-mediated blood-brain barrier
disruption, T-lymphocyte infiltration, astrocyte dysfunction, and complement-mediated
dysregulation of synaptic pruning. This evidence satisfies all nine Bradford Hill criteria to
support causation, and aligns with established principles of toxicology, immunology, and
neurodevelopment [Tomljenovic & Shaw 2011; Grandjean & Landrigan 2014; Vallese et al.
2024; Wei et al. 2011; Saghazadeh et al. 2019].
Yet this robust body of mechanistic and neuropathological evidence remains systematically
marginalized within mainstream vaccine safety discourse—not because it lacks scientific
merit, but because it confronts structural barriers embedded in the institutions charged
with safeguarding public health. These barriers include regulatory capture by industry
interests [Carpenter & Moss, 2014; Abraham, 2002; Maynard & Bloor, 2015], reliance on
population-level epidemiology incapable of detecting subgroup vulnerabilities [DeLong,
2011; Institute of Medicine, 2012], peer review gatekeeping that privileges null findings
32
over mechanistic discovery [Ioannidis, 2022; Horton, 2015], and legal frameworks that
shield manufacturers from accountability while denying compensation to injured children
[IOM, 2010; Bruesewitz v. Wyeth, 2011].
Other vaccine components and delivery factors may also contribute to neurodevelopmental
risk in susceptible populations and warrant inclusion in causation discussions. These
include: (1) mercury from thimerosal (ethylmercury), historically present in multi-dose
vials and until very recently still used in some influenza vaccines, which has been linked to
mitochondrial dysfunction, oxidative stress, and neuroinflammation in animal and cell
models [Geier et al., 2009; Kern et al., 2016]; (2) live attenuated viruses (e.g., in MMR),
which can induce transient immune activation and molecular mimicry in genetically
predisposed children [Singh et al., 2002]; (3) other adjuvants such as squalene (in some
formulations) and AS03/AS04 oil-in-water emulsions, which may amplify systemic
inflammation [Shaw et al., 2013]; (4) combination effects of multiple simultaneous antigens
and adjuvants at well-child visits, potentially overwhelming immature immune and
detoxification systems [DeLong, 2011]; and (5) residual contaminants or manufacturing
byproducts (e.g., polysorbate 80, formaldehyde traces), which have been hypothesized to
disrupt blood-brain barrier integrity or glial function in early development [Shaw &
Tomljenovic, 2013]. These additional factors do not diminish the central role of aluminum
but suggest that the total immunologic and toxicologic burden of the schedule—rather than
any single component—may be the critical driver in genetically susceptible children.
The convergence of mechanistic, neuropathological, genetic, and epidemiological lines of
evidence around aluminum exposure however, paints a compelling yet disturbing picture
where the exquisitely timed processes of synaptic pruning, myelination, and circuit
refinement are disrupted during the critical 3-month to 3-year developmental window. The
resulting neuropathology provides a coherent biological substrate for the core ASD
phenotype: impaired social communication networks, sensory hypersensitivity, repetitive
behaviors, and motor/coordination deficits. While no single study proves causation in
isolation, the satisfaction of all nine Bradford Hill criteria across independent lines of
inquiry, together with reproducible animal-model reversibility and human postmortem
findings, demands urgent, transparent, and rigorous re-examination of aluminum adjuvant
safety in the context of early childhood neurodevelopment. The scale of the current ASD
crisis—now affecting 1 in 31 children with societal costs approaching half a trillion dollars
annually—requires nothing less than a complete paradigm shift in how we evaluate and
regulate vaccine components that enter the developing nervous system during its most
vulnerable period.